Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 9/20 | 0.62 |
| ▸ | ALOX5AP | P20292 | 9/20 | 0.62 |
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29817861 | 1.00 | FEN1 (0.62) | FEN1ALOX5APASIC3GSK3AGSK3B | |
| SCHEMBL1304066 | 0.85 | RAB9A (0.52) | TLR9 | |
| SCHEMBL31518972 | 0.83 | FEN1 (0.49) | FEN1ALOX5AP | |
| SCHEMBL903602 | 0.80 | RAB9A (0.50) | — | |
| SCHEMBL27736012 | 0.80 | MAPK1 (0.44) | FEN1ALOX5APTLR9HSP90AA1 | |
| SCHEMBL557611 | 0.79 | HSP90AA1 (0.56) | FEN1ALOX5APHSP90AA1 | |
| SCHEMBL30414619 | 0.79 | HSP90AA1 (0.56) | FEN1ALOX5APHSP90AA1 | |
| SCHEMBL27928313 | 0.79 | ALOX5AP (0.54) | FEN1ALOX5AP | |
| SCHEMBL6700757 | 0.78 | PIK3CG (0.47) | FEN1ALOX5AP | |
| SCHEMBL4474224 | 0.78 | FEN1 (0.51) | FEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923185-B2 | Pyrazine containing charge transport layer photoconductors | XEROX CORPORATION (US) | 2011-04-12 | — | — | US | claimed |
| US-20090274968-A1 | PYRAZINE CONTAINING CHARGE TRANSPORT LAYER PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2009-11-05 | — | — | US | claimed |
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | UNIVERSITY CATHOLIQUE DE LOUVAIN (BE) | 2004-02-19 | — | — | US | claimed |
| EP-1292580-A1 | PYRAZINE AND IMIDAZOPYRAZINE DERIVATIVES AS ANTIOXIDANTS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2003-03-19 | — | — | EP | claimed |
| WO-2001087853-A1 | ARYL-SUBSTITUTED N,N-HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS AND DIAGNOSTICS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2001-11-22 | — | — | WO | claimed |
| US-12616753-B2 | HSP70 inhibitors and methods of using same | THE WISTAR INSTITUTE (US) | 2026-05-05 | — | — | US | disclosed |
| US-12145949-B2 | Cyclic supported catalysts | Universite Paris-Saclay (FR) | 2024-11-19 | — | — | US | disclosed |
| US-20240368206-A1 | CYCLIC SUPPORTED CATALYSTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-11-07 | — | — | US | disclosed |
| CN-118047654-A | Process for preparing aryl halides starting from aromatic amines | 黑龙江立科新材料有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| US-20230158146-A1 | HSP70 Inhibitors and Methods of Using Same | THE WISTAR INST (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230158146-A1 | HSP70 Inhibitors and Methods of Using Same | THE WISTAR INST (US) | 2023-05-25 | — | — | US | disclosed |
| US-4293552-A | Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-RE30563-E | Preparation of benzoylureas | ELI LILLY AND COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| US-4193995-A | B-ADRENERGIC BLOCKING AGENTS | MERCK SHARP & DOHME (I.A.) CORP. (US) | 1980-03-18 | — | — | US | disclosed |
| US-4160834-A | INSECTICIDES | ELI LILLY AND COMPANY (US) | 1979-07-10 | — | — | US | disclosed |
| US-4133956-A | Preparation of benzoylureas | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4083977-A | Novel insecticidal 1-(substituted benzoyl)-3-(substituted pyrazinyl)ureas | ELI LILLY AND COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
| US-4042586-A | ADRENERGIC BLOCKING AGENTS | MERCK SHARP & DOHME (I.A.) CORPORATION (US) | 1977-08-16 | — | — | US | disclosed |
| US-3946009-A | ADRENERGIC BLOCKING AGENTS | MERCK SHARP & DOHME (I.A.) CORPORATION (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158146-A1 | HSP70 Inhibitors and Methods of Using Same | HSPA2, HSPBP1, HSP90AB1 | FEN1 3467/4885ALOX5AP 2649/4885ASIC3 4306/4885 |
| US-20240368206-A1 | CYCLIC SUPPORTED CATALYSTS | CYCS, CALU, CALD1 | FEN1 1830/4885ALOX5AP 3513/4885ASIC3 2229/4885 |
| US-12616753-B2 | HSP70 inhibitors and methods of using same | HSPB1, HSP90AB1, HSF1 | FEN1 1996/4885ALOX5AP 4338/4885ASIC3 4070/4885 |
| US-12145949-B2 | Cyclic supported catalysts | CYCS, CALU, CALD1 | FEN1 1830/4885ALOX5AP 3513/4885ASIC3 2229/4885 |
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | NOX5, NOX4, CD22 | FEN1 4761/4885ALOX5AP 889/4885ASIC3 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.